Cipla Limited, a leading global pharmaceutical company and Kemwell Biopharma Private Limited, a leading biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space.
Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmceutical products. Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to market.
Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said: “This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership. Guided by our purpose of ‘Caring for life’ our partnership with Kemwell will help serve unmet needs of patients across the globe.”
Forecasts by Capacity (Up to 10L, 11–100L, 101–500L, 501–1500L, Above 1500L), by Components (Media Bags (2D/3D), Single-Use Vessels, Tubing and Connectors, Filtration Assemblies), by Molecule Type (Monoclonal Antibodies, Vaccines, Gene-Modified Cells, Stem Cells, Recombinant Proteins, Other), by SUB Type (Stirred-Tank SUBs, Wave-Induced SUBs, Bubble-Column SUBs), End-user, (Biopharmaceutical Companies, Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMOs), Academic & Research Institutes, Other), by Application (Research and Development (R&D), Process Development, Bioproduction, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading SUB Companies AND COVID-19 Recovery ScenariosDownload free sample pages
Anurag Bagaria, Chairman and Chief Executive Officer of Kemwell, said: “We are very excited about combining the strengths of Cipla’s expertise in development and commercialisation of respiratory products and Kemwell’s biologics capabilities. Through this JV, we aim to make cost-effective biotherapeutics available to more patients globally.”
Date: Aug 25, 2021
Share this news: